Industry

Findings from KONFIDENT and KONFIDENT-S show rapid, effective treatment of HAE attacks among European participants; patient survey highlights barriers linked to injectable therapies FRAMINGHAM, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data from its KONFIDENT and KONFIDENT-S studies of EKTERLY® (sebetralstat), the first and only oral on-demand treatment for hereditary … [Read more…]

Company highlights innovative biologic solutions and hosts Taste of Iceland event featuring a keynote on soft-tissue repair NEW ORLEANS–(BUSINESS WIRE)–#kerecis–Kerecis, the company pioneering the use of sustainably sourced fish skin in cellular therapy and tissue regeneration, will present its expanding portfolio of fish-skin grafts at Plastic Surgery The Meeting (“PSTM”) 2025, taking place October 9–12 … [Read more…]

The collaboration with Amgen reduces out-of-pocket costs for patients and expands access to an innovative cholesterol-lowering therapy SANTA MONICA, Calif.–(BUSINESS WIRE)–GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of Repatha® (evolocumab), a cholesterol-lowering therapy, at a significantly reduced cash price. Starting today, patients can use GoodRx to … [Read more…]

DENVER & MINNEAPOLIS–(BUSINESS WIRE)–OneMedNet Corporation (Nasdaq: ONMD) has selected Palantir Technologies (Nasdaq: PLTR) to transform the healthcare AI and Real-World Data (RWD) analytics marketplace. Palantir’s Artificial Intelligence Platform will provide the infrastructure for OneMedNet’s iRWD™ near real-time AI powered provider network (“network”) enabling OneMedNet to empower life sciences, medical device, and research organizations with anonymized, … [Read more…]

Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only therapy to significantly improve overall survival versus chemotherapy in this patient population DATROWAY also demonstrated a highly statistically significant and clinically meaningful improvement in the dual primary endpoint of progression-free survival Plans for global regulatory submissions are underway TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Positive topline … [Read more…]

Kronos, once valued at $3.5B, Had Two Phase 2 Stage Assets CAMBRIDGE, England–(BUSINESS WIRE)–Ignota Labs, the AI drug turnaround company, has announced its acquisition of Kronos’s clinical assets, istisociclib, a CDK9 inhibitor, and entospletinib and lanraplenib, SYK inhibitors. Kronos’ valuation peaked at $3.5 billion after its IPO; however, it failed to progress its assets past … [Read more…]

MISSISSAUGA, Ontario–(BUSINESS WIRE)–MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that it has completed the Initial Closing of the Non-brokered Private Placement to accredited investors announced in its Press Release dated July 25, 2025. The Initial Closing comprised the issuance of 7,033,000 Units (as described below) and raised cash proceeds … [Read more…]

Anniversary celebration Kicks off at AHF’s original AIDS thrift store location Saturday, October 4th Celebration: 10:00 a.m. – 2:00 p.m. Atwater Village LOS ANGELES–(BUSINESS WIRE)–AIDS Healthcare Foundation (AHF) will mark the 35th anniversary of its award-winning Out of the Closet (OTC) thrift store chain with a celebration and anniversary sale on Saturday, October 4th at … [Read more…]

CHARLOTTESVILLE, Va.–(BUSINESS WIRE)–BUILT Biotechnologies, an emerging leader in DNA Manufacturing-as-a-Service, today announced its selection as an anchor company at the Commonwealth BioAccelerator, an initiative led by CvilleBioHub to strengthen Virginia’s biotechnology ecosystem. The relocation of BUILT’s headquarters to CvilleBioHub’s state-of-the-art facilities at North Fork Research Park positions the company to rapidly scale production in a … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Lymphoma Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2030” report has been added to ResearchAndMarkets.com’s offering. This report gives comprehensive overview of the current scenario of antibody drug conjugates in lymphoma therapy. It identifies the recent clinical trials, technology advancements, and market players influencing the market. … [Read more…]